Products and
Pipeline

«Back

TAK-605*

Oncolytic Virus Solid Tumors

Overview1

- TAK-605 (TBio-6517; RIVAL-01) is a candidate from Turnstone Biologic’s oncolytic vaccinia virus platform, engineered for enhanced immune-stimulation and tumor cell selectivity, potent oncolysis and large transgene carrying capacity

- Turnstone and Takeda will co-develop and co-commercialize TAK-605 (TBio-6517; RIVAL-01) under a 50:50 global profit share

MOA2

TAK-605 (TBio-6517; RIVAL-01) consists of the vaccinia virus backbone encoding transgenes for FIt3 ligand, anti-CTLA-4 antibody and IL-12 p35 cytokine

Clinical Trials
Study Name

A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered by Intratumoral Injection, Alone and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors

CT.GOV ID

NCT04301011

Phase

Phase l/2a

Status

Recruiting

References

1. Turnstone Biologics Press Release.

2. Takeda, Data on file.

Disclaimers

*In collaboration with Turnstone Biologics.

Chat with
Med Info!
chatbot
×

Takeda Live Chat

×
Confirm Exit?

On exiting, all chat history will be cleared